Although combined immunotherapy is currently favored as the first therapy for metastatic melanoma, for advanced patients with unresectable and metastatic BRAF-mutated melanoma with high symptomatic disease burden, the combined BRAFi/MEKi targeted therapy remains the primary option due to its stronger/faster initial response [11,16]. Here, BRAF is linked to melanoma.